Precision LBx Summit San Diego, California, USA 30 January - 1 February, 2017

Description:
Touted as the “holy grail” of diagnostics, liquid biopsy promises real time longitudinal patient monitoring and cost effective diagnostic screening. However, still in its infancy, the field is grappling with proving and advancing the clinical utility of liquid biopsies.

Coinciding with the first FDA approval of a clinical liquid biopsy test, the inaugural Precision LBx Summit will help large biopharma, research laboratories and diagnostic organizations capitalize on this potential.

Prices:
Conference Only (Industry): USD 2699,
Conference + 1 Workshop (Industry): USD 3198,
Workshop Only (Industry): USD 699

Speakers: Stefan Scherer (Vice President, Global Head Correlative Science, Novartis), Pallavi Sachdev (Associate Director, Oncology Biomarker Research, Clinical Development, Eisai), Kenneth Thress (Director, Oncology Translational Science, Astrazeneca), Thomas Schlange (Senior Biomarker Scientist, Bayer & EFPIA Coordinator, IMI Cancer-ID), Jean-Francois Martini (Senior Director, Translational Oncology, EDTO group, Pfizer), George Vasmatzis (Co-Director Biomarker Discovery Program, Center for Individualized Medicine, Mayo Clinic), Samir Hanash (Director, Red & Charline McCombs Institute for the Early Detection & Treatment of Cancer, The University of Texas MD Anderson Cancer Center)